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Summary A multiplex polymerase chain reaction (PCR) was developed for the
simultaneous detection of Chlamydia pneumoniae, Mycoplasma pneumoniae and
Legionella pneumophila. Oligonucleotide primers for the amplification of the DNA of
these three organisms were optimized for use in combination in the same reaction.
PCR products were detected by the Micro-Chip Electrophoresis Analysis System.
Clinical samples were obtained from 208 community-acquired pneumonia (CAP)
patients who were participants in a multicenter CAP surveillance study performed at
seven medical schools and their affiliate hospitals in Japan. No significant
differences in the sensitivity of each primer set were observed when tested in both
the multiplex and monoplex PCR assays. Our multiplex PCR was able to reliably
detect 10 copies/100 ml of each of the three pathogen DNAs. Of the panel of 208
samples, 14 of 15 C. pneumoniae, 10 of 10M. pneumoniae, eight of eight L.
pneumophila and 165 of 176 negative samples were correctly identified. Eleven
cases who were the multiplex PCR positive and conventional method negative were
observed. The PCR findings were of possible significance in at least four of these
patients. Our multiplex PCR assay could potentially be used as a diagnostic and
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epidemiological tool. Further prospective studies are needed to establish its clinical
usefulness.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Atypical pathogens including Chlamydia pneumo-
niae, Mycoplasma pneumoniae and Legionella
pneumophila are an important cause of commu-
nity-acquired pneumonia (CAP). Chlamydia pneu-
moniae and Mycoplasma pneumoniae are the most
common pathogens in the outpatient setting and
high incidences have been recorded in hospitalized
patients with CAP.1–3 L. peumophila has also been
seen in the outpatient setting,2,3 but this pathogen
has been identified with the common organism in
patients with CAP requiring the intensive care
unit.1 The incidence of infection with these
atypical pathogens has been as high as 40–60% of
all admitted patients, often as part of a mixed
infection in Western countries.4 In Japan, there
have been some reports on the etiology of CAP
among the Japanese population.5–7 All these
studies demonstrated that C. pneumoniae and M.
pneumoniae are common pathogens, the third or
fourth leading pathogens, and that the etiology of
CAP in Japan does not differ significantly from that
of Western countries.
Current methods for the identification of atypical
pathogens include culturing, rapid antigen detec-
tion assays, serology and molecular techniques.
Cell cultures for detection of C. pneumoniae
require specialized laboratories and are expensive,
time-consuming and labor-intensive. Since
M. pneumoniae and L. pneumophila grow slowly
and lack sensitivity, the clinical usefulness of
cultures is limited. Rapid laboratory tests such as
antigen detection or hybridization are of limited
sensitivity. Serology usually requires documenta-
tion of a rise in antibody concentration from an
acute phase serum sample to a convalescent phase
serum sample, and thus, test results come in too
late to be of relevance for the treatment of acute
disease.
Currently available nucleic acid amplification
(NAA) techniques, such as the polymerase chain
reaction (PCR), are highly sensitive techniques for
the rapid detection of nucleic acid sequences from
viruses and bacteria in clinical specimens. These
NAA techniques are particularly advantageous for
the detection of fastidious or difficult to culture
organisms such as atypical pathogens. Several
conventional PCR assays have been developed and
have demonstrated sensitivity and specificity equal
to or even better than those of conventional
microbiologic tests.8,9 More recently, multiplex
PCR assays for the simultaneous detection of
different pathogens have been developed.10–13
Here, we report on the development and evalua-
tion of a multiplex PCR for the simultaneous
detection of C. pneumoniae, M. pneumoniae and
L. pneumophila in respiratory samples.
Subjects and methods
Origin of the samples
Nasopharyngeal swab specimens which were col-
lected during a multicenter CAP surveillance study
and stored at 201C were used in this study. A
multicenter CAP surveillance study was performed
in seven medical schools and their affiliate hospi-
tals in Japan, including the University of the
Ryukyus, Kagoshima University, Nagasaki University
School of Medicine, Kurume University School of
Medicine, Toho University School of Medicine,
Tohoku University, Kawasaki Medical School and
their affiliate hospitals between December 1999
and March 2000. The diagnosis was based on clinical
signs and symptoms (cough, fever, productive
sputum, dyspnea, chest pain, or abnormal breath
sounds) and radiographic pulmonary abnormalities
that were at least segmental and were due to
preexisting or other known causes. Two hundred
and thirty-nine CAP patients were enrolled in this
study and eventually 208 patients (17–99 years of
age; 120 males and 88 females) were analyzed.
Microbiologic laboratory tests
Blood cultures and nasopharyngeal swab specimens
were obtained from 64% and 100% of the patients,
respectively; when sputum was available, a Gram’s
stain test and a quantitative culture was obtained.
Sputum data were only evaluated when the Gram’s
stain test revealed numerous leukocytes (425 in a
100microscopic field) and few squamous epithe-
lial cells (o10 in a 100microscopic field). Certain
invasive methods such as bronchoscopic examina-
tion were employed to obtain specimens in some
patients after full explanation of the procedures.
These specimens were also used for culturing of
Legionella spp. on buffered charcoal-yeast extract
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alpha agar. Cultures for C. pneumoniae and C.
psittaci were performed in cycloheximide-treated
HEp-2 cells grown in a 24-well cell culture plate.14
All specimens were passed twice. Culture confirma-
tion was done by fluorescent-antibody staining with
C. pneumoniae and C. psittaci species-specific and
genus-specific monoclonal antibodies.14
Paired serum samples were collected at intervals
of at least 4 weeks and stored at 701C until
testing. Complement fixation (CF) and passive
agglutinin (PA) tests were used to detect antibodies
to M. pneumoniae. Antibodies to Legionella spp.
and Coxiella burnetii were measured by the
indirect immunofluorescence test. The micro-im-
munofluorescence test was used for titration of IgG
and IgM antibodies against Chlamydia spp. using
formalinized elementary bodies of the C. pneumo-
niae TW-183 (purchased from the Washington
Research Foundation, Seattle, WA, USA) and
KKpn-15,15 C. trachomatis L2/434/Bu and C.
psittaci 6BC strains as antigens. Sera with IgM
against Chlamydia spp. were retested after absorp-
tion with goat anti-human IgG antibody reagent
(Gullsorb; Gull Laboratories, Salt Lake City, UT,
USA) in order to exclude false-positive reactions.
Antibodies to viruses such as influenza A and B
viruses, adenovirus, respiratory syncytial virus,
cytomegalovirus and parainfluenza virus types 1, 2
and 3 were measured at Kitasato-Otsuka virus assay
laboratory. In addition to serology and culturing,
the urinary antigen test was used for detection
of L. pneumophila (NOW Legionella; Binax Inc.,
Portland, USA).
Criteria for determination of microbial
etiology
Bacteria were considered to be definitive causative
agents when isolated from blood culture. We
considered the results of sputum cultures in
combination with Gram’s stain findings. An organ-
ism showing heavy (^107 colony-forming units
[CFU]/ml) growth of a predominant bacterium on
a sputum culture or moderate (105–6 CFU/ml)
growth of a culture with phagocytosis observed by
Gram’s stain was considered to be a definitive
pathogen. If an organism showing moderate growth
of a predominant bacterium on a sputum culture
without phagocytosis was observed by Gram’s stain,
that specimen was judged by the medical doctor
according to clinical findings and course. If Legio-
nella spp. was isolated from a specimen, that
specimen was considered to be a definitive patho-
gen even if the culture showed little growth. L.
pneumophila was considered to be a presumptive
agent when the urinary antigen test result was
positive. For serologic tests, a four-fold rise in the
antibody titer level between paired sera was
considered definitive. C. pneumoniae infection
was defined as IgM ^1:32 or a four-fold rise in IgG
or IgM.
DNA extraction
A 1ml aliquot of specimens was centrifuged at
15,000g for 10min at room temperature. Most of
the supernatant was discarded and 200ml, includ-
ing the pellets, were recovered and incubated with
protenase K (20 ml) in AL buffer (200 ml, Qiagen) for
10min at 561C. Subsequently, the samples were
mixed with 100% ethanol (200 ml). The DNA was
extracted using the Qiagen DNA mini kit (QIA amp,
Qiagen) according to the manufacturer’s recom-
mendations. Then samples were treated with
ethanol three times. DNA was eluted in a final
volume of 200 ml, aliquoted, and stored at 201C
before performance of the PCR.
Multiplex PCR
Target sequences were regions of the major outer
membrane protein gene for C. pneumoniae (CPN
25: 50-CTC GTT GGT TTA TTC GGA GTT AAA G-30,
CPN 26: 50-GAG AAT TGC GAT ACG TTA CAG ATC A-
30), the nucleotide sequence of the 16S rRNA for M.
pneumoniae (MP 6: 50-ATT GCC TTG GTA GGC CGT
TAC CCC AC-30, MP 8: 50-CAA AGT TGA AAG GAC CTG
CAA G-30) and the major outer membrane protein
porin gene for L. pneumophila (LPN 15: 50-AGT GCT
TTG TTT GCA GGT ACG-30, LPN 16: 50-CAC CAA CAT
CAG TAA AAC CAT TAT AGC-30). PCR reactions for
these three pathogens were initially evaluated
separately using serial dilutions of culture materi-
als. The reactions were subsequently combined.
Optimization of the multiplex assay was performed
by testing different combinations of primer con-
centrations and magnesium concentrations, using a
fixed dilution of the culture materials at about 2 log
above the detection threshold of the individual
assays, to establish a combination with the most
comparable result. Finally, the reaction conditions
of the multiplex PCR were 10mM Tris–HCl, 50mM
KCl, 1.5mM MgCl2, 5% dimethylsufoxide, 200 mM
dNTPs, 5 U AmpliTaq DNA polymerase and the
presence of concentrations (0.2–0.4 mM) of three
primer pairs (Applied Biosystems). The PCR was
performed in a Gene Amp PCR system 9600-R
(Perkin-Elmer) with the following thermal profile:
10min at 951C, followed by 40 cycles of 30 s at
941C, 30 s 601C and 60 s 721C and one cycle for
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10min at 721C. PCR product detection was per-
formed with the Micro-Chip Electrophoresis Analy-
sis System (SV1210 Cosmoeye, Hitachi).16 The
appearance of 236, 157 and 88 base pair amplifica-
tion products corresponding to C. pneumoniae, L.
pneumophila and M. pneumoniae, respectively,
was considered to be a positive reaction. In each
experiment, negative and positive controls for each
pathogen were used. Positive controls were made
with the PCR-TOPO 2.1 cloning kit (Invitrogen).
Sensitivity and specificity of the multiplex
PCR
The sensitivity of the PCR assay was determined
using serial 10-fold dilutions of DNA samples from
C. pneumoniae (ATCC VR-2282), M. pneumoniae
(ATCC 29342) and L. pneumophila (ATCC 33153)
with known starting concentrations. The specificity
of the multiplex PCR was assessed using isolates of
one of the following pathogens: Aspergillus fumi-
gatus, Aspergillus spp., Candida albicans, Candida
spp., C. pneumoniae, C. trachomatis, C. psittaci,
Escherichia coli, Haemophilus influenzae, Haemo-
philus spp., Klebsiella pneumoniae, Klebsiella
spp., L. pneumophila, Legionella spp., M. pneu-
moniae, Mycoplasma spp., Staphylococcus aureus,
Staphylococcus spp., Streptococcus pneumoniae, S.
pyogenes, S. agalactiae, adenovirus 1, 2, 3, 5, 7
and 11, Cytomegalovirus, Epstein Barr virus, herpes
simplex virus, influenza virus A and B, parainfluenza
virus 1, 2 and 3, Respiratory cyncitial virus and
varicella zoster virus.
Results
Sensitivity and specificity of the multiplex
PCR
The reproducibility of the cut-off results was
determined by testing duplicates of a 10-fold serial
dilution of the positive controls in 10 independent
experiments. No significant differences in the
sensitivity of each primer set were observed when
tested in both the multiplex and monoplex PCR
assays. Our multiplex PCR was able to reliably
detect 10 copies/100 ml of each of the three
pathogen DNAs. We also measured the amount of
DNA of the PCR products in each of the three
pathogens in 10 independent experiments. Based
on the results from average DNA concentrations,
we decided the level of semi-quantitation as
follows: 10 copies/100 ml indicate þ , 102 copies/
100 ml indicate 2þ and 103 copies/100 ml indicate
3þ . The specificity of the PCR reaction was
considered satisfactory as no specific amplification
was noted with any of the tested pathogens.
Analysis of C: pneumoniae; M: pneumoniae
and L: pneumophila infections using
respiratory samples with CAP
Among our 208 CAP cases, the most common
pathogens were Streptococcus pneumoniae, found
in 52 cases, followed by Haemophilus influenzae in
38 cases, C. pneumoniae in 15 cases, M. pneumo-
niae in 10 cases, L. pneumophila in eight cases,
Staphylococcus aureus in seven cases and Moraxella
catarrahalis in five cases by using the conventional
methods (culture, serology or antigen detection
test). All 15 cases of C. pneumoniae demonstrated
four-fold or greater rises in IgG antibody titers and
five cases demonstrated positive IgM antibody
titers. No culture-positive patient was observed
among these cases. Of the 15 cases, C. pneumoniae
was the only pathogen identified in nine cases
(60.0%), while one or more additional etiological
agents was found in six cases (40.0%). The
additional pathogens were S. pneumoniae in two,
H. influenzae in two, M. catarrahalis in two and M.
pneumoniae in one. Among all the mixed-C.
pneumoniae pneumonia cases, one additional
agent was found in five cases and two additional
agents were found in one case. All 10 cases of M.
pneumoniae demonstrated four-fold or greater
rises in CF or PA antibody titers. Of the 10 cases,
one additional etiological agents was found in three
cases (30.0%). The additional pathogens were S.
pneumoniae in two and C. pneumoniae in one.
Among eight cases of L. pneumophila, all cases
demonstrated four-fold or greater rises in antibody
titers and one culture-positive patient and two
urinary antigen-positive patients were observed. Of
the eight cases, one or more additional etiological
agents was found in four cases. The additional
pathogens were H. influenzae in two, S. pneumo-
niae in one, M. catarrahalis in one and C. psittaci in
one. Among all the mixed-L. pneumophila pneu-
monia cases, one additional agent was found in
three cases and two additional agents were found
in one case.
A total of 208 CAP cases were investigated by the
multiplex PCR. The multiplex PCR results were
concordant with those obtained by conventional
methods for the 208 cases, with positive concor-
dant results for 31 cases (13 for C. pneumoniae,
nine for M. pneumoniae, one for dual infection with
C. pneumoniae and M. pneumoniae and eight for L.
pneumophila) and negative concordant results for
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165 cases (Table 1). Discrepant results were
observed in 12 cases. An overall agreement of
94.2% with conventional methods was obtained for
the 208 cases.
The details of C. pneumoniae, M. pneumoniae
and L. pneumophila positive cases using conven-
tional methods and Multiplex PCR results are listed
in Table 2. Of these, only one discrepant result was
observed in a patient (patient No. 2) who was
serology-positive for C. pneumoniae (four-fold rise
in both IgM and IgG antibody titer) but multiplex
PCR-negative. In this case, a diagnosis of C.
pneumoniae pneumonia was made because of the
serological result, the absence of other respiratory
pathogens and his response to macrolide. This
might suggest that the amount of DNA in this
sample was below the detection limit. Dual infec-
tion with C. pneumoniae and M. pneumoniae was
observed in only one patient (patient No. 15) and
the multiplex PCR was also positive in both
pathogens.
Among the 208 CAP cases, 11 cases who were the
multiplex PCR positive and conventional method
negative were observed, one for C. pneumoniae,
five for M. pneumoniae, one for dual infection with
C. pneumoniae and M. pneumoniae and four for
L. pneumophila (Table 3). On the basis of bacterial
cultures, clinical features and the response to
antibiotics, the multiplex PCR results were con-
sidered significant in three of these 11 cases
(patient No. 3, 9, and 11). In one other case
(patient No. 10), another significant bacterial
pathogen was isolated, but on the basis of the
response to the prescribed antibiotic, the role of L.
pneumophila could not be excluded. Seven other
cases had DNA with one of the three atypical
pathogens, but all responded to antibiotics not
suitable for the treatment of atypical pathogens.
Though the PCR results in these seven cases may
seem irrelevant, they may simply indicate that in
the normal host these infections are self-limiting.
Discussion
The etiologic diagnosis of infections with atypical
pathogens such as C. pneumoniae, M. pneumoniae
and L. pneumophila still remains difficult. This is
mainly due to difficulties in culturing and to the
delayed results associated with conventional meth-
ods (serology and culturing), which often allow a
retrospective diagnosis only. The current develop-
ment of NAA techniques should offer a highly
sensitive, specific and rapid diagnosis of CAP. In
this study, we reported the successful development
of a multiplex PCR for the simultaneous detection
and differentiation of C. pneumoniae, M. pneumo-
niae and L. pneumophila.
In the experiments performed with clinical
specimens, it was possible to test all specimens
simultaneously for the presence of nucleic acids
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Table 1 Comparison of multiplex PCR and conventional methods for 208 patients.
Multiplex PCR One hundred
and sixty six
patients
negative for
the three
pathogens
Forty-two patients for
C. pneumoniae M. pneumoniae L. pneumophila
Patients with conventional
methods positive for
C. pneumoniae 14n 1
M. pneumoniae 10n 0
L. pneumophila 8 0
Patients with conventional
methods negative for the three
pathogens
2n 6n 4 165
nIncluding one patient with dual infection with C. pneumoniae and M. pneumoniae infection.
546 N. Miyashita et al.
from three atypical pathogens with comparatively
little effort, thus indicating that this method is
well-suited for use in epidemiological studies as
well as for rapid microbiological studies in the
clinical setting. Tong et al.10 reported good agree-
ment of a multiplex PCR and conventional methods
using a panel of known positive and negative
samples for M. pneumoniae, C. pneumoniae and
C. psittaci. Of their panel of 53 samples, nine of
11M. pneumoniae, 11 of 11 C. pneumoniae, six of
seven C. psittaci and 24 of 24 negative samples
were correctly identified. Welti et al.13 also
reported good agreement of a multiplex real-time
PCR and serology using 38 patients with C.
pneumoniae, M. pneumoniae or L. pneumophila
respiratory tract infections. Of 19 serology-positive
patients, 14 were confirmed by the multiplex real-
time PCR to be infected by one of the three
pathogens. All samples from serology-negative
patients were negative with the multiplex real-
time PCR. In our study, all but one sample from
conventional method positive patients were also
positive with the multiplex PCR. In addition, 165
samples from conventional method negative pa-
tients were also negative with the multiplex PCR
(Table 1). Our results are consistent with these
reported by Tong et al.10 and Welti et al.13 and
indicate that the multiplex PCR assay is a useful
and rapid diagnostic tool for the management of
community-acquired atypical pneumonia.
Grondahl et al.11 reported a multiplex reverse
transcription-PCR protocol for detecting up to nine
different respiratory agents, including C. pneumo-
niae and M. pneumoniae, in children. But that
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Table 2 Test results of the positive members of the evaluation panel.
Patient no. Multiplex PCR C. pneumoniae M. pneumoniae L. pneumophila
CP MP LP Serology Culture Serology Serology Culture Urinary antigen
1 2þ F F þ F F F F F
2 F F F þ F F F F F
3 2þ F F þ F F F F F
4 þ F F þ F F F F F
5 þ F F þ F F F F F
6 þ F F þ F F F F F
7 þ F F þ F F F F F
8 þ F F þ F F F F F
9 þ F F þ F F F F F
10 þ F F þ F F F F F
11 þ F F þ F F F F F
12 þ F F þ F F F F F
13 þ F F þ F F F F F
14 þ F F þ F F F F F
15 þ 2þ F þ F þ F F F
16 F 2þ F F F þ F F F
17 F 2þ F F F þ F F F
18 F þ F F F þ F F F
19 F 2þ F F F þ F F F
20 F 2þ F F F þ F F F
21 F 2þ F F F þ F F F
22 F þ F F F þ F F F
23 F þ F F F þ F F F
24 F 2þ F F F þ F F F
25 F F þ F F F þ þ þ
26 F F þ F F F þ F þ
27 F F þ F F F þ F F
28 F F þ F F F þ F F
29 F F þ F F F þ F F
30 F F þ F F F þ F F
31 F F þ F F F þ F F
32 F F þ F F F þ F F
CP¼Chlamydia pneumoniae; MP¼Mycoplasma pneumoniae; LP¼ Legionella pneumophila.
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Table 3 Clinical features, bacterial culture results and treatment responses of the 11 patients who had a positive multiplex PCR result.
Patient
no.
Age
(year)
Sex Underlying
conditions
Bacterial
culture results
Initial antibiotic
treatment
Response of
initial
treatment
Further
treatment
Multiplex PCR
resutls
Relevance and
significance of
PCR result
1 89 M Pulmonary
emphysema
S. pneumoniae PIPC Yes None C. pneumoniae No
2 58 M Heart disease H. influenzae CTM Yes None C. pneumoniae No
FMOX M. pneumoniae
3 27 F None Normal flora CAM Yes None M. pneumoniae Yes
4 47 F None Normal flora SBT/ABPC Yes None M. pneumoniae No
5 80 F None Normal flora CLDM Yes None M. pneumoniae No
6 73 M Old pulmonary
tuberculosis
S. pneumoniae
M. catarrahalis
PIPC Yes None M. pneumoniae No
7 55 M Liver
dysfunction
Normal flora PAPM/BP Yes None M. pneumoniae No
8 29 M None Normal flora CAM No PIPC L. pneumophila No
9 48 M Heart disease Normal flora CAM Yes None L. pneumophila Yes
10 76 M Bladder Ca. H. influenzae CFPM No IPM/CS L. pneumophila Possible
EM
Steroid
11 29 F None Normal flora CAM Yes None L. pneumophila Yes
PIPC¼piperacillin sodium; CTM¼ cefotiam HCl; FMOX¼flomoxef sodium; CAM¼ clarithromycin; SBT/ABPC¼ sulbactam/ampicillin; CLDM¼ clindamycin; PAPM/BP¼panipenem/
betamipron; CFPM¼ cefepime HCl; IPM/CS¼ imipenem/cilastatin; EM¼erythromycin.
5
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study reported a low detection rate for C.
pneumoniae in contrast to other studies.17,18 This
may reflect a specimen choice problem; i.e.,
nasopharyngeal aspirates versus swabs, as sug-
gested by the same authors.19 It has been suggested
that the sensitivity of PCRs differ when different
types of respiratory samples are used and that the
highest sensitivity and specificity to diagnose C.
pneumoniae, M. pneumoniae and L. pneumophila
could be obtained with sputum and broncho
alveolar lavage.20,21 Therefore, more studies using
different types of specimens are needed to
evaluate our multiplex PCR assay.
One of the characteristics of NAAs is their ability
to detect non-viable organisms that have not been
cleared, especially after antibiotic treatment.22
Several studies suggest that many cases of CAP with
an undetermined etiologic diagnosis are associated
with previous antibiotic administration.23,24 Thus
while antibiotic treatment compromises the chance
of bacterial isolation, PCR detection is not affected
by the lack of viability of the pathogens and is more
sensitive than cultures for the detection of atypical
pathogens in respiratory specimens.10 In contrast,
prolonged and asymptomatic shedding of C. pneu-
moniae and M. pneumoniae has been re-
ported.17,18,25–30 Therefore, one should be aware
that when using a sensitive PCR technique, it is
possible to detect a persistent bacterial genome for
a prolonged period. In this study, we also analyzed
the 11 patients who were multiplex PCR positive
but conventional method negative with regard to
whether the episode of CAP was caused by the
identified organism. Some patients (Table 3, No. 3,
9, and 11) responded to initial treatment with the
appropriate antibiotic for M. pneumoniae and L.
pneumophila and no other significant bacterial
pathogens were isolated in these patients. So, the
multiplex PCR result was considered significant in
these three cases. In contrast, several patients
(Table 3, No. 1, 2, 4, 5, 6, 7, and 8) were treated
with inappropriate antibiotics for atypical patho-
gens and appeared to have a prolonged or
asymptomatic infection. Overall, we believe that
in at least four of 11 patients in this series, the
finding of M. pneumoniae or L. pneumophila could
be clinically relevant.
In conclusion, we have successfully developed a
rapid, highly sensitive and specific semi-quantita-
tive multiplex PCR that can simultaneously detect
and differentiate three causative agents of atypical
pneumonia. To study the usefulness of this assay in
a clinical context, it is necessary to carry out
prospective studies covering both epidemic and
non-epidemic periods, using different types of
respiratory samples.
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